2024-03-25T05:27:07-05:00 2023-12-31 221478099 COHNREZNICK LLP 490 SAWGRASS CORPORATE PARKWAY SUITE 200 SUNRISE FL 333256254 990 2023-01-01 271263151 HEART INITIATIVE INC HEAR 9192871824 50101 GOVERNORS DR CHAPEL HILL NC 275179517 BETH COTTER-DAVISON DIRECTOR 9192871824 2024-03-22 1 BETH COTTER-DAVISON XXX-XX-XXXX 1 ZVI RAFILOVICH CPA P00056952 9549743544 2024-03-21 3 AAL1 IAL1 2023 2023-04-26 12:10:37Z BETH COTTER-DAVISON 1717 N BAYSHORE DR APT 1034 MIAMI FL 33134 1147740 0 X HTTP://WWW.WORLDHEARTINITIATIVE.ORG X 2009 NC HEART INITIATIVE, (F/K/A AFRICAN HEART INITIATIVE) (THE "CORPORATION") IS A NON-PROFIT ORGANIZATION. 3 0 0 0 0 0 3106327 1077725 0 0 22726 70015 0 0 3129053 1147740 25000 56073 0 0 0 0 0 0 0 2439025 2410515 2464025 2466588 665028 -1318848 2497807 1950272 80000 851313 2417807 1098959 X DURING 2023 THE HEART INITIATIVE CONTINUED ITS SCIENTIFIC MISSION TO IMPROVE HEART FAILURE THERAPY GLOBALLY THROUGH TWO MAIN AVENUES: 1. PUBLICATIONS AND SHARING OF DATA FROM STUDIES COMPLETED THE HEART FROM STUDIES COMPLETED IN PREVIOUS YEARS AND SHARE THEM WITH THE SCIENTIFIC COMMUNITY. SUCH EXAMPLES ARE HIGHLIGHTED IN THE LINKS BELOW. AMONG THE CONTRIBUTING MEMBERS OF OUR RESEARCH ORGANIZATION. HTTPS://PUBMED.NCBI.NLM.NIH.GOV/36356631/ 0 0 2466588 56073 70015 DURING 2023 THE HEART INITIATIVE HAS CONTINUED TO SUMMARIZE AND ANALYZE THE STRONG HF STUDY - A PLACEBO CONTROLLED STUDY PERFORMED GLOBALLY ASSESSING THE IMPLEMENTATION OF APPROVED, GENERIC MEDICATION FOR THE TREATMENT OF HF IN PATIENTS RECENTLY ADMITTED FOR ACUTE HEART FAILURE. THE RESULTS OF THE STUDY WERE ANALYZED, PRESENTED, AND PUBLISHED. THEY ARE EXPECTED TO HAVE SIGNIFICANT IMPACT FOR THE TREATMENT OF HEART FAILURE, A DISEASE THAT INFLICTS APPROXIMATELY 6 MILLION AMERICANS AND IS ASSOCIATED WITH HIGH MORBIDITY AND MORTALITY. IN ADDITION, THE HEART INITIATIVE IS ACTIVELY CONTINUING TO ANALYZE AND PUBLISH DATA FROM THE COMPLETED STUDIES BOTH CONDUCTED IN SUB SHARAN AFRICA. IN 2023, THE HEART INITIATIVE HAS STARTED TWO NEW INTITIATIVES (1) THE ROBUST HF REGISTRY WHICH WILL HELP IMPLEMENT THE RESULTS OF THE STRONG HF STUDY GLOBALY AND (2) THE CORTHAF STUDY, A NEW INITIATIVE TO TEST THE USE OF STEODIS PULSE THERAPY IN ACUTE HEART FAILURE. 2466588 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 X 3 0 1 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 X ROBERT MOLINA 9192871824 50101 GOVERNORS DR CHAPEL HILL NC 27517 GAD COTTER DIRECTOR 15.00 X 0 0 0 BETH COTTER-DAVISON DIRECTOR 15.00 X 0 0 0 ROBERT MOLINA DIRECTOR 2.00 X 0 0 0 0 0 0 0 0 0 0 0 1077725 1077725 32387 32387 37628 0 37628 37628 37628 1147740 70015 0 0 X 56073 56073 2408919 2408919 BANK SERVICE CHARGES 1596 1596 2466588 2466588 0 0 X 213799 13 0 340856 2271110 1594856 12898 14547 2497807 1950272 80000 840456 10857 80000 851313 X 0 0 0 0 2417807 1098959 2417807 1098959 2497807 1950272 -1318848 0 X 0 0 0 X 1309052 3667190 657669 3106327 1077725 9817963 1309052 3667190 657669 3106327 1077725 9817963 0 0 0 9817963 818 3318 16481 22726 32384 75727 818 3318 16481 22726 32384 75727 25823 25823 1309870 3696331 674150 3129053 1110109 9919513 0.98980 0.99320 0.00760 0.00440 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 1 ITALY 0 0 GRANT TO SPEDALI CIVILI CARDIOLOGIA TO SUPPORT THE CARDIOLOGY UNIT ACTIVITIES. 56073 0 0 0 0 0 0 56073 0 56073 ITALY TO SUPPORT THE CARDIOLOGY UNIT ACTIVITIES AT ASST SPEDALI CIVILI CARDIOLOGIA DI BRESCIA 56073 WIRE TRANSFER 0 FMV 1 0 0 0 0 0 0 MOMENTUM RESEARCH INC DIRECTORS ARE SHAREHOLDERS OF MOMENTUM RESEARCH INC 2115469 PROFESSIONAL FEES 0 MOMENTUM RESEARCH FRANCE SAS DIRECTORS ARE INDIRECT SHAREHOLDERS OF MOMENTUM RESEARCH FRANCE SAS 313000 PROFESSIONAL FEES 0 SCH L, PART IV, BUSINESS TRANSACTIONS INVOLVING INTERESTED PERSONS: FORM 990, PART I, LINE 1, DESCRIPTION OF ORGANIZATION MISSION: CREATED IN 2009. ORIGINALLY, THE MISSION OF THE CORPORATION WAS TO COLLABORATE WITH CARDIOVASCULAR LEADERS IN AFRICA TO IMPROVE THE EARLY DIAGNOSIS AND TREATMENT OF CARDIOVASCULAR DISEASES AND HEART FAILURE IN SUB-SAHARAN AFRICA, PARTICULARLY INCREASING USAGE OF PROVEN THERAPIES FOR HEART FAILURE AND IMPROVE ADHERENCE. THROUGH THE COURSE OF ITS WORK, THE CORPORATION'S ACTIVITIES AND RESEARCH HAVE EVOLVED. THE CORPORATION HAS PARTNERED WITH MOMENTUM RESEARCH, INC., LARIBOISIRE HOSPITAL IN PARIS, AND ROCHE DIAGNOSTICS TO EXAMINE OTHER ASPECTS OF EARLY DIAGNOSIS AND TREATMENT OF CARDIOVASCULAR DISEASE, SPECIFICALLY HEART FAILURE, BEYOND AFRICA. MISSION AND ACCOMPLISHMENTS: DURING 2023 THE HEART INITIATIVE CONTINUED ITS SCIENTIFIC MISSION TO IMPROVE HEART FAILURE THERAPY GLOBALLY THROUGH TWO MAIN AVENUES: 1. PUBLICATIONS AND SHARING OF DATA FROM STUDIES COMPLETED THE HEART FROM STUDIES COMPLETED IN 2022 AND PREVIOUS YEARS AND SHARE THEM WITH THE SCIENTIFIC COMMUNITY. SUCH EXAMPLES ARE HIGHLIGHTED IN THE LINKS BELOW AMONG THE CONTRIBUTING MEMBERS OF OUR RESEARCH ORGANIZATION. HTTPS://PUBMED.NCBI.NLM.NIH.GOV/36356631/ 2. PERFORMING STUDIES TO PROMOTE BETTER HEART HEALTH GLOBALLY, THE HEART INITIATIVE HAS CONTINUED TO SPONSOR ITS LARGEST STUDY TO DATE THE STRONG-HF STUDY WHICH IS AIMED AT BETTER IMPLEMENTING CHEAP, GENERIC THERAPIES IN PATIENTS AFTER AND ADMISSION TO A HOSPITAL FOR HEART FAILURE. IN 2022, THE HEART INITIATIVE SECURED ADDITIONAL SPONSORSHIP FROM ROCHE DIAGNOSTICS TO ENABLE EXPANDING THE STUDY TO UP TO 1,100 PATIENTS AND CONTINUES TO RECRUIT PATIENTS TO THE STUDY GLOBALLY IN EUROPE, SOUTH AMERICA AND SUBSAHARAN AFRICA. IN 2022, THE STUDY WAS COMPLETED AND ANALYZED, PRESENTED AND PUBLISHED. 3. THE HEART INITIATIVE AS WITH ITS PARTNERS AT ISNERM HAVE INITIATED A NEW STUDY TO EXPLORE THE EFFECTS OF STEROIDS IN AHF. THE STUDY TITLE IS "EFFECT OF SHORT-TERM PREDNISONE THERAPY ON C-REACTIVE PROTEIN CHANGE IN EMERGENCY DEPARTMENT PATIENTS WITH ACUTE HEART FAILURE AND ELEVATED INFLAMMATORY MARKERS" ACUTE HEART FAILURE (AHF) IS A COMMON DISCHARGE DIAGNOSIS IN THE EMERGENCY DEPARTMENT (ED), ASSOCIATED WITH 1-MONTH MORTALITY OF 6%, AND A 30% RISK RATE OF 1-MONTH REHOSPITALIZATION. CURRENT GUIDELINES RECOMMEND THE USE OF NITRATES AND LOW DOSE DIURETIC TO TREAT CONGESTION, BUT TO DATE, NO DRUG HAS EVER SHOWN ANY IMPROVED CLINICAL OUTCOME WHEN GIVEN AT THE ACUTE PHASE. SEVERAL STUDIES SUGGEST THAT THERE IS A HIGH INFLAMMATORY COMPONENT IN AHF, WITH ELEVATED MARKERS SUCH AS IL6 AND C-REACTIVE PROTEIN (CRP). AS IT IS THE CASE IN OTHER ACUTE RESPIRATORY DISEASE, A SHORT COURSE OF STEROID THERAPY MAY LIMIT THE INFLAMMATORY RESPONSE AND IN TURN, IMPROVE AHF PROGNOSIS. THE OBJECTIVE OF THE STUDY IS TO ASSESS THE EFFECT OF A 7-DAY COURSE OF STEROID INTRODUCED IN THE ED ON INFLAMMATORY RESPONSE. THE STUDY IS A PARALLEL-GROUP, RANDOMIZED, OPEN-LABEL, CONTROLLED TRIAL IN 5 EDS IN FRANCE. PATIENTS WITH AHF AND HIGH CRP LEVELS WILL BE RANDOMIZED TO 7 DAYS OF PREDNISONE THERAPY OR CONTROL AND FOLLOWED FOR 30DAYS. ENDPOINTS INCLUDE CHANGE IN CRP LEVELS AND RISK OF WORSENING HF, HF READMISSION OR DEATH TO DAY 30. 4. THE HEART INITIATIVE AND ITS PARTNERS IN MOUNT SINAI HOSPITAL IN NYC HAVE INITIATED A STUDY TO ASSESS WAYS TO IMPROVE ADHERENCE IN PATIENTS WITH HTN AND HYPERLIPIDEMIA. THE STUDY ENTILTLED: "CP&R - CARDIOVASCULAR PRECISION MEDICINE & REMOTE INTERVENTION". CONTROL OF HYPERTENSION AND HYPERCHOLESTEROLEMIA IS KEY TO REDUCING RISK OF ADVERSE CARDIOVASCULAR OUTCOMES IN PATIENTS WITH CARDIOVASCULAR MORBIDITY. NON-ADHERENCE TO MEDICAL RECOMMENDATIONS IS THE MOST IMPORTANT REASON FOR ADVERSE OUTCOMES, AS BLOOD PRESSURE REMAINS ERRATIC IF MEDICATION-TAKING IS ALSO ERRATIC. NON-ADHERENCE CAN BE IDENTIFIED BY MULTIPLE SUBJECTIVE AND OBJECTIVE METHODS, BUT SUBJECTIVE METHODS (PATIENTS' OWN REPORTS) ARE NOT RELIABLE, AND OBJECTIVE METHODS MAY BE MISLEADING (IF THEY ARE DEPENDENT ON FACTORS OTHER THAN ADHERENCE), OR CUMBERSOME. FOR EXAMPLE, ELECTRONIC MONITORING OF ADHERENCE TENDS TO REQUIRE THE USE OF A SPECIFIC DEVICE, AND THE MOST NON-ADHERENT PATIENTS TEND NOT TO BE ABLE TO CONSISTENTLY USE THE DEVICE, RESULTING IN STUDY DESIGNS THAT FAVOR ADHERENT PATIENTS (IN STUDIES THAT PURPORT TO IMPROVE ADHERENCE). THE PRESENT STUDY USES A NOVEL INDICATOR FOR NON-ADHERENCE BASED ON ELECTRONIC HEALTH RECORD (EHR) DATA: THE DEGREE OF VARIABILITY OF BLOOD PRESSURE MEASUREMENTS OVER TIME. RISK STRATIFICATION BY A VARIABILITY MARKER WILL BE COUPLED WITH REMOTE INTERVENTION OFFERED ONLY TO PATIENTS WHO ARE AT INCREASED RISK. THE INTERVENTION WILL BE TARGETED AT THE POSSIBLE ROOT CAUSES OF THESE PATIENTS' NON-ADHERENCE. THE INNOVATIONS IN OUR APPROACH ARE THE USE OF A MARKER DERIVED FROM EHR INFORMATION TO TARGET THE INTERVENTION (RESULTING IN BETTER RESOURCE ALLOCATION), THE REMOTE INTERVENTION THAT DOES NOT REQUIRE IN-PERSON MEETINGS WHICH MAY BE HARD TO IMPLEMENT ESPECIALLY WITH PATIENTS WHO ARE NON-ADHERENT TO THEIR MEDICAL RECOMMENDATIONS ANYWAY, AND THE FLEXIBLE AND ADAPTABLE INTERVENTION THAT IS CUSTOMIZED FOR EACH PATIENT. 5. THE HEART INITIATIVE INITIATED A NEW STUDY, ROBUST HF, WHICH WILL HELP IMPLEMENT THE RESULTS OF STRONG HF GLOBALLY. THE STUDY WAS THE MAIN FOCUS OF THE HEART INITIATIVE IN 2023. FORM 990, PART VI, SECTION A, LINE 2 GAD COTTER AND BETH COTTER-DAVIDSON ARE DIRECTORS AND MARRIED TO EACH OTHER. FORM 990, PART VI, SECTION B, LINE 11B NO REVIEW WAS OR WILL BE CONDUCTED. FORM 990, PART VI, SECTION C, LINE 19 NO OTHER DOCUMENTS AVAILABLE TO THE PUBLIC. FORM 990, PART IX, LINE 11G PROFESSIONAL FEES: PROGRAM SERVICE EXPENSES 2,408,919. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 2,408,919.